Patients with a methylated MGMT promoter had a mean survival of 322 days, while those without methylation had a median survival of 373 days (p=0.75), the mean PFS of the 2 groups with MGMT methylated and unmethylated MGMT were 326 days and 270 days, respectively (p=0.6).